Azithromycin

Azithromycin is a semisynthetic antibiotic belonging to the macrolide subgroup of azalides and is similar in structure to erythromycin.
azithromycin reaches high intracellular concentrations (due to chlamydia and gonorrhea), thus increasing efficacy and duration of action. 

Azithromycin’s innovator is Pfizer-Global and is known world-wide by the brand names: Zithromax, Zithromax tri-Pak and Zithromax Z-Pak.

Azithromycin inhibits protein synthesis in bacterial cells by binding to the 50S subunit of bacterial ribosomes. Action is generally bacteriostatic but can be bactericidal in high concentrations or against susceptible organisms. Azithromycin is more active against gram-negative organisms but has less activity against streptococci and staphylococci than does erythromycin. In addition to chlamydial infections, it is also useful for treating mild to moderate upper respiratory infections and mild community-acquired pneumonia. It is not clear if Azithromycin, like erythromycin, is effective in the treatment of diabetic gastroparesis.

Azithromycin concentrates in fibroblasts, epithelial cells, macrophages, and circulating neutrophils and monocytes. In vitro incubation techniques of Azithromycin have shown that the ratio of intracellular to extra cellular concentration was more than 30 after one hour incubation. In vivo studies suggest that concentration in macrophages and circulating white blood cells may contribute to drug distribution to inflamed tissues.
Azithromycin is generally active against organisms that are usually susceptible to erythromycin. These include gram-positive organisms, such as Staphylococcus aureus, Streptococcus agalactiae, S. pyogenes, and S. pneumoniae, and gram-negative Haemophilus influenzae and Moraxella catarrhalis. Chlamydia trachomatis is also susceptible to Azithromycin.
Other organisms that have shown in vitro susceptibility include streptococci (Groups C, F, and G), Streptococcus viridans group, Bordetella pertussis, Campylobacter jejuni, Haemophilus ducreyi, Legionella pneumophilia, Bacteroides bivius, Clostridium perfringens, Peptostreptococcus species, Mycoplasma pneumoniae, Treponema pallidum, and Ureaplasma urealyticum. Azithromycin’s tissue penetration and very low MIC of Azithromycin against Borrelia burgdorferi (the causative agent of Lyme disease) suggest it may be useful in treating this serious disease.

Azithromycin comes in tablets of 250 mg, 500 mg and 600 mg.

General data on Azithromycin Active Pharmaceutical Ingredient

CAS Registry: 83905-01-5 (anhydrous azithromycin); 117772-70-0 (azithromycin dihydrate)
ATC: J01FA10; S01AA26
Molecular Formula: C38H72N2O12, 2H2O
Molecular Weight: 785.0

TAPI's Azithromycin Pharmaceutical Ingredient

TAPI's Azithromycin Active Pharmaceutical Ingredient is produced in Assia Chemical Industries Limited - Teva Tech site in Beer Sheva, Israel.

Azithromycin is produced by TAPI by Semi-Synthetic – Antibiotic synthesis and is considered to be high volume Active Pharmaceutical Ingredient.

 2008 Available DMF: U.S. DMF, EU CTD, CEP, Korea DMF and Turkey DMF.

TAPI provides full service on this product and other APIs in our portfolio. Our local sales offices provide full information on our product, regulatory compliance and documentation on Azithromycin. Contact us today for further inquiries and samples and kilograms availability information for TAPI's Azithromycin

Another product, in the group of ANTIBACTERIALS - Macrolides available on TAPI's portfolio is: Clarithromycin. Contact us today for information on these products.

Legal Note

Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products  that  Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1).

*TAPI stands for Teva's Active Pharmaceutical Ingredients